RCM
RCKTW

Radcliffe Capital Management’s Rocket Pharmaceuticals Warrant RCKTW Stock Holding History

Radcliffe Capital Management’s Portfolio RCKTW Stock Details RCKTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-85,765
Closed -$15K – 229
2023
Q3 		$15K Buy
+85,765
New +$13.5K ﹤0.01% 299

Other funds holding RCKTW

BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Radcliffe Capital Management's RCKTW Position: Q4 2023 in Review

Radcliffe Capital Management sold out of Rocket Pharmaceuticals Warrant (RCKTW) in Q4 2023, closing a stake of 85,765 shares — an estimated $15K sold.

Radcliffe Capital Management first reported a position in RCKTW in Q3 2023 and held it in 1 quarter. The position peaked at $15K in Q3 2023. 14 funds tracked by Wall St. Rank hold RCKTW as of Q4 2023.

  • Radcliffe Capital Management reported no remaining Rocket Pharmaceuticals Warrant position as of Q4 2023 after selling out during the quarter.
  • Radcliffe Capital Management sold 85,765 Rocket Pharmaceuticals Warrant shares in Q4 2023, an estimated $15K.
  • Radcliffe Capital Management first reported a position in Rocket Pharmaceuticals Warrant in Q3 2023 and held it in 1 quarter.
  • Radcliffe Capital Management's Rocket Pharmaceuticals Warrant position peaked at $15K in Q3 2023.
  • 14 funds tracked by Wall St. Rank held Rocket Pharmaceuticals Warrant as of Q4 2023.

Based on Radcliffe Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.